A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors.
Eukaryotic elongation factor 2 kinase (eEF2K) inhibitors may aid in the development of new therapeutic agents to combat cancer. Purified human eEF2K was obtained from anEscherichia coliexpression system and a luminescence-based high-throughput screening (HTS) assay was developed using MH-1 peptide as the substrate. The luminescent readouts correlated with the amount of adenosine triphosphate remaining in the kinase reaction. This method was applied to a large-scale screening campaign against a diverse compound library and subsequent confirmation studies. Nine initial hits showing inhibitory activities on eEF2K were identified from 56,000 synthetic compounds during the HTS campaign, of which, five were chosen to test their effects in cancer cell lines.
The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Department of Pharmacy, Medical College of Nanchang University, Nanchang 330066, China.
Ting
T
Xiao
Center for Biological Sciences, Life Sciences Building, University of Southampton, Southampton SO16 7LB, UK; South Australian Health and Medical Research Institute, North Terrace, Adelaide SA5000, Australia.
Rui
R
Liu
Center for Biological Sciences, Life Sciences Building, University of Southampton, Southampton SO16 7LB, UK; South Australian Health and Medical Research Institute, North Terrace, Adelaide SA5000, Australia.
Christopher G
CG
Proud
The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Ming-Wei
MW
Wang
High-throughput screening; Inhibitors; Luminescence; MH-1 peptide; eEF2K